一拆二,直接裁员40%

谈思生物
10 Jan

02025.01.10本文字数:1530,阅读时长大约4分钟导读:Galapagos公司转型与拆分计划**:面临业务困境,Galapagos计划于2025年年中拆分为两家独立上市公司,削减40%员工。核心产品Filgotinib美国上市受阻,转型细胞疗法效果不及预期。拆分后,一家公司继续沿用Galapagos名称,聚焦细胞疗法,握有5亿欧元现金;另一家SpinCo获24.5亿欧元现金支持,专注管线...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10